MX2024007220A - Psicoplastogenos de pirrolidina fusionada y sus usos. - Google Patents
Psicoplastogenos de pirrolidina fusionada y sus usos.Info
- Publication number
- MX2024007220A MX2024007220A MX2024007220A MX2024007220A MX2024007220A MX 2024007220 A MX2024007220 A MX 2024007220A MX 2024007220 A MX2024007220 A MX 2024007220A MX 2024007220 A MX2024007220 A MX 2024007220A MX 2024007220 A MX2024007220 A MX 2024007220A
- Authority
- MX
- Mexico
- Prior art keywords
- psychoplastogens
- fused pyrrolidine
- disorders
- compounds
- methods
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
- C07D487/14—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
- C07D491/14—Ortho-condensed systems
- C07D491/147—Ortho-condensed systems the condensed system containing one ring with oxygen as ring hetero atom and two rings with nitrogen as ring hetero atom
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Addiction (AREA)
- Epidemiology (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
En el presente documento, se divulgan compuestos, composiciones y métodos para promover el crecimiento neuronal y/o mejorar la estructura neuronal con los compuestos y composiciones divulgados en el presente documento. También se describen métodos para tratar enfermedades o trastornos que están mediados por la pérdida de conectividad y/o plasticidad sináptica, tales como enfermedades y trastornos neurológicos, con psicoplastógenos de pirrolidina fusionada.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163290037P | 2021-12-15 | 2021-12-15 | |
| US202263387225P | 2022-12-13 | 2022-12-13 | |
| PCT/US2022/052879 WO2023114320A1 (en) | 2021-12-15 | 2022-12-14 | Fused pyrrolidine psychoplastogens and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2024007220A true MX2024007220A (es) | 2024-08-27 |
Family
ID=86773439
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2024007220A MX2024007220A (es) | 2021-12-15 | 2022-12-14 | Psicoplastogenos de pirrolidina fusionada y sus usos. |
Country Status (9)
| Country | Link |
|---|---|
| EP (1) | EP4448532A4 (es) |
| JP (1) | JP2025502614A (es) |
| KR (1) | KR20240150418A (es) |
| AU (1) | AU2022415426A1 (es) |
| CA (1) | CA3239571A1 (es) |
| IL (1) | IL313457A (es) |
| MX (1) | MX2024007220A (es) |
| TW (1) | TW202333736A (es) |
| WO (1) | WO2023114320A1 (es) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4351548A4 (en) | 2021-06-08 | 2025-04-30 | ATAI Therapeutics, Inc. | Dimethoxyphenylalkylamine activators of serotonin receptors |
| MX2024007221A (es) | 2021-12-15 | 2024-08-27 | Delix Therapeutics Inc | Psicoplastogenos sustituidos con fenoxi y benciloxi y sus usos. |
| JP2024547131A (ja) | 2021-12-27 | 2024-12-26 | エーティーエーアイ セラピューティクス，インコーポレイテッド | セロトニン受容体のアミノテトラリン活性化剤 |
| US12343319B2 (en) | 2023-05-01 | 2025-07-01 | Atai Therapeutics, Inc. | Compositions and methods for treatment of diseases and disorders |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL184490B1 (pl) * | 1995-02-02 | 2002-11-29 | Smithkline Beecham Plc | Nowe pochodne indolu jako antagonista receptora T |
| PE20010052A1 (es) * | 1999-04-23 | 2001-01-27 | Upjohn Co | Compuestos de azepinindol tetraciclico como agonistas o antagonistas del receptor de 5-ht |
| WO2002024700A2 (en) * | 2000-09-20 | 2002-03-28 | Pharmacia & Upjohn Company | SUBSTITUTED AZEPINO[4,5b]INDOLINE DERIVATIVES |
| EP1632491A1 (en) * | 2004-08-30 | 2006-03-08 | Laboratorios Del Dr. Esteve, S.A. | Substituted indole compounds and their use as 5-HT6 receptor modulators |
| US20230295106A1 (en) * | 2019-10-14 | 2023-09-21 | The Regents Of The University Of California | Ergoline-like compounds for promoting neural plasticity |
-
2022
- 2022-12-14 JP JP2024533214A patent/JP2025502614A/ja active Pending
- 2022-12-14 MX MX2024007220A patent/MX2024007220A/es unknown
- 2022-12-14 EP EP22908391.0A patent/EP4448532A4/en active Pending
- 2022-12-14 CA CA3239571A patent/CA3239571A1/en active Pending
- 2022-12-14 IL IL313457A patent/IL313457A/en unknown
- 2022-12-14 KR KR1020247023489A patent/KR20240150418A/ko active Pending
- 2022-12-14 AU AU2022415426A patent/AU2022415426A1/en active Pending
- 2022-12-14 TW TW111148111A patent/TW202333736A/zh unknown
- 2022-12-14 WO PCT/US2022/052879 patent/WO2023114320A1/en not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| AU2022415426A1 (en) | 2024-07-25 |
| WO2023114320A1 (en) | 2023-06-22 |
| TW202333736A (zh) | 2023-09-01 |
| IL313457A (en) | 2024-08-01 |
| EP4448532A4 (en) | 2025-12-24 |
| CA3239571A1 (en) | 2023-06-22 |
| JP2025502614A (ja) | 2025-01-28 |
| KR20240150418A (ko) | 2024-10-15 |
| EP4448532A1 (en) | 2024-10-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2024007220A (es) | Psicoplastogenos de pirrolidina fusionada y sus usos. | |
| MX2022001607A (es) | Composiciones y metodos para tratar la psoriasis y la dermatitis atopica usando prevotella histicola. | |
| SA521422031B1 (ar) | مركبات 2 – فورميل – 3 – هيدروكسي فينيلوكسي ميثيل قادرة على تعديل الهيموجلوبين | |
| MX2024006123A (es) | Triptaminas especificas para usarse en el tratamiento de trastornos de estado de animo. | |
| MX2021013197A (es) | Cicloalquilos sustituidos como moduladores de la vía integrada del estrés. | |
| PH12021553145A1 (en) | Multispecific heavy chain antibodies binding to cd22 and cd3 | |
| MX2022016415A (es) | Inhibidores de glicolato oxidasa para el tratamiento de enfermedades. | |
| PH12022553019A1 (en) | Il-17a modulators | |
| MX2025002953A (es) | Derivados heteroaromaticos y aromaticos heterobiciclicos para el tratamiento de trastornos relacionados con ferroptosis | |
| ZA202211667B (en) | Multispecific heavy chain antibodies with modified heavy chain constant regions | |
| MX2023010711A (es) | Fenalquilaminas y métodos de preparación y uso de las mismas. | |
| WO2022031847A3 (en) | Compositions and methods for inhibiting plp1 expression | |
| PH12022500021A1 (en) | Il-17a modulators | |
| ZA202100672B (en) | Further substituted triazolo quinoxaline derivatives | |
| WO2022218941A3 (en) | Compositions and methods for inhibiting ketohexokinase (khk) | |
| MX2023004942A (es) | Compuestos biciclicos y usos de los mismos para el tratamiento de enfermedades. | |
| MX2025007384A (es) | Inhibidores de malt1 | |
| MX2021012129A (es) | Composiciones y método para utilizarlas para el tratamiento de enfermedades neurodegenerativas y mitocondriales. | |
| MX2023005591A (es) | Metodos de tratamiento de enfermedades y trastornos. | |
| MX2021000762A (es) | Derivados de triazoloquinoxalina sustituida. | |
| PH12021552377A1 (en) | Novel compounds and pharmaceutical compositions thereof for the treatment of inflammatory disorders | |
| WO2019066549A3 (ko) | 망막 기능장애 질환 치료를 위한 유전자 조작 | |
| WO2020142740A8 (en) | Treatment of sjogren's disease with nuclease fusion proteins | |
| MX2025005627A (es) | Anticuerpos que se unen al componente de complemento 1s (c1s) y usos de estos | |
| WO2021100029A3 (en) | Prodrugs of fulvestrant |